Amino acids

Protecting a Most Precious Asset: GABA Proved to Fortify Cognitive Health in Human Trials

Tuesday, March 31, 2020 - 12:00pm

They want to have agency over the state of their mental health as they age, as they do their physical health.

Key Points: 
  • They want to have agency over the state of their mental health as they age, as they do their physical health.
  • The benefits of the naturally-occurring amino acid neurotransmitter GABA [-Aminobutyric acid], found across a range of healthful foods, have never really been in doubt.
  • It has long been known that a decreased systemic level of GABA is associated with the presence of Parkinsons disease, epilepsy, Huntingtons chorea, Alzheimers disease, and schizophrenia.
  • The current studies published by Pharma Foods International offer the promise that a naturally-occurring, naturally derived supplement, GABA, may lead the way.

DGAP-News: Newly published data in Cancer Immunology, Immunotherapy support the potential of Secarna Pharmaceuticals' LNA-modified ASOs to effectively block important immunosuppressive pathway

Thursday, March 26, 2020 - 8:01am

DGAP-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Scientific publication

Key Points: 
  • DGAP-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Scientific publication
    Newly published data in Cancer Immunology, Immunotherapy support the potential of Secarna Pharmaceuticals' LNA-modified ASOs to effectively block important immunosuppressive pathway
    The issuer is solely responsible for the content of this announcement.
  • Both targets are catalytic enzymes that play a key role in an important immunosuppressive pathway - the degradation of tryptophan into kynurenine.
  • Secarna's approach also was shown to be synergistic with one of the clinically most advanced IDO1-specific small molecule inhibitors (epacadostat).
  • The published data show that treatment of cancer cells with LNAplusTM-modified ASOs specific for IDO1 and TDO2 lead to potent target knockdown in vitro.

Animal Feed Amino Acids Market to Reach Valuation of ~US$ 14.1 Bn by 2027; Developing Concerns About Animal Health Stimulates the Growth of Global Market, Noted TMR

Wednesday, March 18, 2020 - 11:30am

To provide precise analysis of the market, the report classifies the global animal feed amino acids market into various segments.

Key Points: 
  • To provide precise analysis of the market, the report classifies the global animal feed amino acids market into various segments.
  • Explore the latest study on global animal feed amino acids market under the title: Animal Feed Amino Acids Market (Product: Tryptophan, Lysine, Methionine, Threonine, and Others; and Application: Ruminants [Cattle, Sheep, and Others], Poultry, Swine, Pets, Equine, Aqua, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 2027 at https://www.transparencymarketresearch.com/animal-feed-amino-acids-market.html
    These insights from the report help the players to understand the factors that are actually driving the growth of global animal feed amino acids market.
  • Global Animal Feed Amino Acids Market: Regional Analysis
    Asia Pacific is expected to dominate the regional front of the global animal feed amino acids market during the tenure of 2019 to 2027.
  • The global animal feed amino acids market is segmented on the basis of:
    Animal Feed Amino Acids Market, by Product

Animal Feed Amino Acids Market to Reach Valuation of ~US$ 14.1 Bn by 2027; Developing Concerns About Animal Health Stimulates the Growth of Global Market, Noted TMR

Wednesday, March 18, 2020 - 11:30am

This demand is propelling the growth of global animal feed amino acids market

Key Points: 
  • This demand is propelling the growth of global animal feed amino acids market
    ALBANY, New York, March 18, 2020 /PRNewswire/ -- Driven by myriad of factors the global animal feed amino acids market is expected to witness a substantial growth during the tenure of 2019 to 2027, says a recent study by Transparency Market Research.
  • Explore the latest study on global animal feed amino acids market under the title: Animal Feed Amino Acids Market (Product: Tryptophan, Lysine, Methionine, Threonine, and Others; and Application: Ruminants [Cattle, Sheep, and Others], Poultry, Swine, Pets, Equine, Aqua, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 2027 at https://www.transparencymarketresearch.com/animal-feed-amino-acids-market.html
    These insights from the report help the players to understand the factors that are actually driving the growth of global animal feed amino acids market.
  • Global Animal Feed Amino Acids Market: Regional Analysis
    Asia Pacific is expected to dominate the regional front of the global animal feed amino acids market during the tenure of 2019 to 2027.
  • The global animal feed amino acids market is segmented on the basis of:
    Animal Feed Amino Acids Market, by Product

Homology Medicines Announces Peer-Reviewed Publication of HMI-102 Investigational Gene Therapy Demonstrating Restoration of Normal Metabolic Pathway in PKU Disease Model

Monday, March 16, 2020 - 1:00pm

The data also demonstrated a concomitant increase in tyrosine (Tyr), a metabolite of Phe and precursor to neurotransmitters, indicating enzymatic activity.

Key Points: 
  • The data also demonstrated a concomitant increase in tyrosine (Tyr), a metabolite of Phe and precursor to neurotransmitters, indicating enzymatic activity.
  • Additionally, brain levels of Phe, 5-HIAA (downstream serotonin metabolite) and coat color were normalized, further indicating restoration of the Phe metabolic pathway.
  • We developed a robust preclinical data package for our investigational HMI-102 gene therapy, which supported the initiation of our ongoing Phase 1/2 pheNIX clinical trial for adults with PKU, stated Albert Seymour, Ph.D., Chief Scientific Officer of Homology Medicines.
  • These published data demonstrated that a single dose of HMI-102 was able to restore the normal biochemical pathway in the established PKU model on normal protein diet.

Methionine Industry Analysis & Outlook, 2020-2025 - Market is Highly Consolidated; Top Four Players Account for >85% of the Market

Tuesday, March 10, 2020 - 9:15pm

Eco-friendly means of extracting methionine is projected to act as an opportunity for the market, in the future.

Key Points: 
  • Eco-friendly means of extracting methionine is projected to act as an opportunity for the market, in the future.
  • The global methionine market is highly consolidated, with the top four players accounting for more than 85% of the market.
  • Key players in the methionine market include Adisseo, Evonik Industries AG, Novus International, Sumitomo Chemical Co. Ltd., and Tokyo Chemical Industry Co. Ltd., among others.
  • By learning and communicating, Chinese and foreign companies can achieve mutual understanding, which may benefit them both in the methionine market.

No More Need for Dieting? AntiCancer’s Oral Methioninase Prevents Mouse Obesity and Diabetes on an Ultra-high-fat Diet

Tuesday, March 10, 2020 - 10:00am

AntiCancer Inc. has announced that its methionine-cleaving enzyme methioninase prevented mice from becoming obese while on an ultra-high fat diet.

Key Points: 
  • AntiCancer Inc. has announced that its methionine-cleaving enzyme methioninase prevented mice from becoming obese while on an ultra-high fat diet.
  • Principal investigator Qinghong Han said, With two oral doses of methioninase per day, dieting will not be necessary in the future, as the methioninase will control excess weight gain.
  • First author Yoshihiko Tashiro said, Methioninase not only prevents obesity but obesity-related diabetes as well.
  • Methioninase is also effective against every type of cancer in mouse models and is proposed as treatment for coronavirus infection.

Pea Protein Market Worth $1,400 Million by 2025 - Exclusive Report by MarketsandMarkets™

Tuesday, March 3, 2020 - 2:30pm

Key factors driving the growth of the pea protein market include the growing vegan population and the functional benefits and allergen-friendly nature of pea protein in food and beverage products.

Key Points: 
  • Key factors driving the growth of the pea protein market include the growing vegan population and the functional benefits and allergen-friendly nature of pea protein in food and beverage products.
  • The textured subsegment, on the basis of type, is projected to be the fastest-growing segment in the pea protein market during the forecast period.
  • Textured pea protein contains a high amount of amino acids and has better levels of lysine and glutamine than other plant-based proteins.
  • The meat substitutes subsegment is projected to account for the largest share in the pea protein market during the forecast period.

Pea Protein Market Worth $1,400 Million by 2025 - Exclusive Report by MarketsandMarkets™

Tuesday, March 3, 2020 - 2:30pm

Key factors driving the growth of the pea protein market include the growing vegan population and the functional benefits and allergen-friendly nature of pea protein in food and beverage products.

Key Points: 
  • Key factors driving the growth of the pea protein market include the growing vegan population and the functional benefits and allergen-friendly nature of pea protein in food and beverage products.
  • The textured subsegment, on the basis of type, is projected to be the fastest-growing segment in the pea protein market during the forecast period.
  • Textured pea protein contains a high amount of amino acids and has better levels of lysine and glutamine than other plant-based proteins.
  • The meat substitutes subsegment is projected to account for the largest share in the pea protein market during the forecast period.

VistaGen Therapeutics Receives FDA Clearance of IND for Phase 2 Clinical Study of AV-101 as a Potential Treatment of Dyskinesia in Parkinson's Disease Patients

Thursday, January 30, 2020 - 1:30pm

The FDA's IND clearance permits VistaGen to proceed with Phase 2 clinical development of AV-101 in this indication.

Key Points: 
  • The FDA's IND clearance permits VistaGen to proceed with Phase 2 clinical development of AV-101 in this indication.
  • "Current drug treatment options for levodopa-induced dyskinesia, or LID, may cause serious side effects, including hallucinations and sedation.
  • In all clinical studies to date, AV-101 has not been associated with any psychotomimetic side effects or drug-related serious adverse events.
  • "These are important milestones for our AV-101 program, both a key regulatory advance and expanded commercial protection for AV-101 in the U.S.